ARWR Valuation

Arrowhead Pharmaceuticals Inc

Add to Watchlist

Advanced Chart

16.420

+0.36(2.242%)1D

Overview
Forecast
Valuation
Earnings

ARWR Relative Valuation

ARWR's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, ARWR is overvalued; if below, it's undervalued.

Historical Valuation

Arrowhead Pharmaceuticals Inc (ARWR) is now in the Undervalued zone, suggesting that its current forward PS ratio of 5.58 is considered Undervalued compared with the five-year average of -29.14. The fair price of Arrowhead Pharmaceuticals Inc (ARWR) is between 711.40 to 775.89 according to relative valuation methord. Compared to the current price of 16.42 USD , Arrowhead Pharmaceuticals Inc is Undervalued By 97.69%.

Relative Value

Fair Zone

711.40-775.89

Current Price：16.42

97.69%

Undervalued

-5.19

Trailing

Forward

-6.88

EV/EBITDA

Arrowhead Pharmaceuticals Inc. (ARWR) has a current EV/EBITDA of -6.88. The 5-year average EV/EBITDA is -30.69. The thresholds are as follows: Strongly Undervalued below -103.72, Undervalued between -103.72 and -67.20, Fairly Valued between 5.82 and -67.20, Overvalued between 5.82 and 42.34, and Strongly Overvalued above 42.34. The current Forward EV/EBITDA of -6.88 falls within the Historic Trend Line -Fairly Valued range.

-5.46

EV/EBIT

Arrowhead Pharmaceuticals Inc. (ARWR) has a current EV/EBIT of -5.46. The 5-year average EV/EBIT is -19.47. The thresholds are as follows: Strongly Undervalued below -109.10, Undervalued between -109.10 and -64.28, Fairly Valued between 25.35 and -64.28, Overvalued between 25.35 and 70.17, and Strongly Overvalued above 70.17. The current Forward EV/EBIT of -5.46 falls within the Historic Trend Line -Fairly Valued range.

5.58

Arrowhead Pharmaceuticals Inc. (ARWR) has a current PS of 5.58. The 5-year average PS is 26.03. The thresholds are as follows: Strongly Undervalued below -1.36, Undervalued between -1.36 and 12.34, Fairly Valued between 39.73 and 12.34, Overvalued between 39.73 and 53.42, and Strongly Overvalued above 53.42. The current Forward PS of 5.58 falls within the Undervalued range.

-11.82

P/OCF

Arrowhead Pharmaceuticals Inc. (ARWR) has a current P/OCF of -11.82. The 5-year average P/OCF is -23.15. The thresholds are as follows: Strongly Undervalued below -164.16, Undervalued between -164.16 and -93.66, Fairly Valued between 47.36 and -93.66, Overvalued between 47.36 and 117.86, and Strongly Overvalued above 117.86. The current Forward P/OCF of -11.82 falls within the Historic Trend Line -Fairly Valued range.

-9.48

P/FCF

Arrowhead Pharmaceuticals Inc. (ARWR) has a current P/FCF of -9.48. The 5-year average P/FCF is 4.75. The thresholds are as follows: Strongly Undervalued below -52.09, Undervalued between -52.09 and -23.67, Fairly Valued between 33.17 and -23.67, Overvalued between 33.17 and 61.59, and Strongly Overvalued above 61.59. The current Forward P/FCF of -9.48 falls within the Historic Trend Line -Fairly Valued range.

Arrowhead Pharmaceuticals Inc (ARWR) has a current Price-to-Book (P/B) ratio of 4.34. Compared to its 3-year average P/B ratio of 11.73 , the current P/B ratio is approximately -62.98% higher. Relative to its 5-year average P/B ratio of 12.75, the current P/B ratio is about -65.94% higher. Arrowhead Pharmaceuticals Inc (ARWR) has a Forward Free Cash Flow (FCF) yield of approximately -0.78%. Compared to its 3-year average FCF yield of -12.44%, the current FCF yield is approximately -93.76% lower. Relative to its 5-year average FCF yield of -7.33% , the current FCF yield is about -89.41% lower.

4.34

P/B

Median3y

11.73

Median5y

12.75

-0.78

FCF Yield

Median3y

-12.44

Median5y

-7.33

Competitors Valuation Multiple

The average P/S ratio for ARWR's competitors is 1008.06, providing a benchmark for relative valuation. Arrowhead Pharmaceuticals Inc Corp (ARWR) exhibits a P/S ratio of 5.58, which is -99.45% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

ARWR.O

Arrowhead Pharmaceuticals Inc

Recursion Pharmaceuticals Inc

Apogee Therapeutics Inc

Loss

2.11B

DNLI.O

Denali Therapeutics Inc

Performance Decomposition

Market capitalization of ARWR decreased by 31.10% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 0.00 to 27.77M.

The secondary factor is the Margin Expansion, contributed -94.76%to the performance.

Overall, the performance of ARWR in the past 1 year is driven by Revenue Growth. Which is more sustainable.

NaN%

0.00 → 27.77M

Revenue Growth

-94.76%

-12.29K → -643.40

Margin Expansion

NaN%

0.00 → -14.42

P/E Change

-31.10%